Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 100

1.

The effect of the combination of bisphosphonates and conventional chemotherapy on bone metabolic markers in multiple myeloma patients.

Zhang X, Chang C, Zhao Y, Wu L, Zhang Z, Li X.

Hematology. 2012 Sep;17(5):255-60. doi: 10.1179/1607845412Y.0000000021.

PMID:
22971530
[PubMed - indexed for MEDLINE]
2.

[The affection of bisphosphonates combined with chemotherapy on bone metabolism index in multiple myeloma].

Zhang X, Chang CK, Wu LY, Zhang Z, Zhou LY, Xiao C, Li X.

Zhonghua Xue Ye Xue Za Zhi. 2011 Oct;32(10):660-3. Chinese.

PMID:
22339822
[PubMed - indexed for MEDLINE]
Free Article
3.

[Efficacy of zoledronic acid combined with chemotherapy in treatment of skeletal metastases of non-small cell lung cancer and the bone metabolic markers].

Hu XY, Zou QF, Jin C, Li WD, Chen WS, Ma L.

Nan Fang Yi Ke Da Xue Xue Bao. 2010 Jun;30(6):1343-6. Chinese.

PMID:
20584674
[PubMed - indexed for MEDLINE]
Free Article
4.

Randomized phase II trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonates.

Fizazi K, Lipton A, Mariette X, Body JJ, Rahim Y, Gralow JR, Gao G, Wu L, Sohn W, Jun S.

J Clin Oncol. 2009 Apr 1;27(10):1564-71. doi: 10.1200/JCO.2008.19.2146. Epub 2009 Feb 23.

PMID:
19237632
[PubMed - indexed for MEDLINE]
5.

Prospective study of urinary and serum cross-linked N-telopeptide of type I collagen (NTx) for diagnosis of bone metastasis in patients with lung cancer.

Tamiya M, Tokunaga S, Okada H, Suzuki H, Kobayashi M, Sasada S, Okamoto N, Morishita N, Matsuura Y, Miyamoto N, Hattori M, Taira K, Daga H, Takeda K, Hirashima T.

Clin Lung Cancer. 2013 Jul;14(4):364-9. doi: 10.1016/j.cllc.2012.11.006. Epub 2012 Dec 29.

PMID:
23276824
[PubMed - indexed for MEDLINE]
6.

[Relationship of osteolytic biochemical indicators of bone metabolism with the therapeutic effect in breast cancer patients with bone metastases].

Li SF, Wang XR, Wang C, Chen Y, Ren L, Cui L, Tong ZS.

Zhonghua Zhong Liu Za Zhi. 2009 Dec;31(12):911-5. Chinese.

PMID:
20193330
[PubMed - indexed for MEDLINE]
7.

Additive effect of zoledronic acid on serum prostate-specific antigen changes for hormone-sensitive prostate cancer patients with bone metastasis treated by combined androgen blockade.

Kamiya N, Suzuki H, Endo T, Takano M, Yano M, Naoi M, Nishimi D, Kawamura K, Imamoto T, Ichikawa T.

Int J Urol. 2012 Feb;19(2):169-73. doi: 10.1111/j.1442-2042.2011.02914.x. Epub 2011 Nov 29.

PMID:
22126137
[PubMed - indexed for MEDLINE]
8.

Serial markers of bone turnover in men with metastatic prostate cancer treated with zoledronic Acid for detection of bone metastases progression.

Lein M, Wirth M, Miller K, Eickenberg HU, Weissbach L, Schmidt K, Haus U, Stephan C, Meissner S, Loening SA, Jung K.

Eur Urol. 2007 Nov;52(5):1381-7. Epub 2007 Feb 20.

PMID:
17321667
[PubMed - indexed for MEDLINE]
9.

Serum N-telopeptide and bone-specific alkaline phosphatase levels in patients with osteonecrosis of the jaw receiving bisphosphonates for bone metastases.

Morris PG, Fazio M, Farooki A, Estilo C, Mallam D, Conlin A, Patil S, Fleisher M, Cremers S, Huryn J, Hudis CA, Fornier MN.

J Oral Maxillofac Surg. 2012 Dec;70(12):2768-75. doi: 10.1016/j.joms.2011.12.028. Epub 2012 Feb 11.

PMID:
22330331
[PubMed - indexed for MEDLINE]
10.

Effect of pamidronate administration on markers of bone turnover and disease activity in multiple myeloma.

Terpos E, Palermos J, Tsionos K, Anargyrou K, Viniou N, Papassavas P, Meletis J, Yataganas X.

Eur J Haematol. 2000 Nov;65(5):331-6.

PMID:
11092464
[PubMed - indexed for MEDLINE]
11.

First-line therapy with thalidomide, dexamethasone and zoledronic acid decreases bone resorption markers in patients with multiple myeloma.

Tosi P, Zamagni E, Cellini C, Parente R, Cangini D, Tacchetti P, Perrone G, Ceccolini M, Boni P, Tura S, Baccarani M, Cavo M.

Eur J Haematol. 2006 May;76(5):399-404. Epub 2006 Feb 15.

PMID:
16480429
[PubMed - indexed for MEDLINE]
12.

Prospective evaluation of the peptide-bound collagen type I cross-links N-telopeptide and C-telopeptide in predicting bone metastases status.

Costa L, Demers LM, Gouveia-Oliveira A, Schaller J, Costa EB, de Moura MC, Lipton A.

J Clin Oncol. 2002 Feb 1;20(3):850-6.

PMID:
11821470
[PubMed - indexed for MEDLINE]
13.

First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trial.

Morgan GJ, Davies FE, Gregory WM, Cocks K, Bell SE, Szubert AJ, Navarro-Coy N, Drayson MT, Owen RG, Feyler S, Ashcroft AJ, Ross F, Byrne J, Roddie H, Rudin C, Cook G, Jackson GH, Child JA; National Cancer Research Institute Haematological Oncology Clinical Study Group.

Lancet. 2010 Dec 11;376(9757):1989-99. doi: 10.1016/S0140-6736(10)62051-X. Epub 2010 Dec 3.

PMID:
21131037
[PubMed - indexed for MEDLINE]
Free PMC Article
14.

Serum biomarkers of bone metabolism in castration-resistant prostate cancer patients with skeletal metastases: results from SWOG 0421.

Lara PN Jr, Ely B, Quinn DI, Mack PC, Tangen C, Gertz E, Twardowski PW, Goldkorn A, Hussain M, Vogelzang NJ, Thompson IM, Van Loan MD.

J Natl Cancer Inst. 2014 Apr;106(4):dju013. doi: 10.1093/jnci/dju013. Epub 2014 Feb 24.

PMID:
24565955
[PubMed - indexed for MEDLINE]
15.

Osteolytic lesions marker in multiple myeloma.

Djunic I, Elezovic I, Marinkovic M, Suvajdzic-Vukovic N, Tomin D, Jankovic G, Bila J, Antic D, Vidovic A, Neskovic B, Nikolic-Vukosavljevic D.

Med Oncol. 2011 Mar;28(1):237-40. doi: 10.1007/s12032-010-9432-4. Epub 2010 Feb 2.

PMID:
20127208
[PubMed - indexed for MEDLINE]
16.

Jaw osteonecrosis associated with use of bisphosphonates and chemotherapy: paradoxical complication of treatment of bone lesions in multiple myeloma patients.

Capalbo S, Delia M, Diomede D, Dargenio M, Chiefa A, Favia G, Liso V.

Int J Hematol. 2006 Jun;83(5):439-42.

PMID:
16787865
[PubMed - indexed for MEDLINE]
17.

Zoledronic acid and survival in patients with metastatic bone disease from lung cancer and elevated markers of osteoclast activity.

Hirsh V, Major PP, Lipton A, Cook RJ, Langer CJ, Smith MR, Brown JE, Coleman RE.

J Thorac Oncol. 2008 Mar;3(3):228-36. doi: 10.1097/JTO.0b013e3181651c0e.

PMID:
18317064
[PubMed - indexed for MEDLINE]
18.

Pamidronate increases markers of bone formation in patients with multiple myeloma in plateau phase under interferon-alpha treatment.

Terpos E, Palermos J, Viniou N, Vaiopoulos G, Meletis J, Yataganas X.

Calcif Tissue Int. 2001 May;68(5):285-90.

PMID:
11683535
[PubMed - indexed for MEDLINE]
19.

Bisphosphonates for breast cancer.

Pavlakis N, Schmidt R, Stockler M.

Cochrane Database Syst Rev. 2005 Jul 20;(3):CD003474. Review. Update in: Cochrane Database Syst Rev. 2012;2:CD003474.

PMID:
16034900
[PubMed - indexed for MEDLINE]
20.

Clinical value of bone remodelling markers in patients with bone metastases treated with zoledronic acid.

Pectasides D, Nikolaou M, Farmakis D, Kanakis I, Gaglia A, Kountourakis P, Karamanos NK, Economopoulos T, Raptis SA.

Anticancer Res. 2005 Mar-Apr;25(2B):1457-63.

PMID:
15865105
[PubMed - indexed for MEDLINE]
Free Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk